Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,127

Document Document Title
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/178795A1
The present disclosure relates to [18F]-labeled benzothiazole derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in ...  
WO/2020/163653A1
Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.  
WO/2020/157184A1
The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety ...  
WO/2020/159904A1
Compounds having the following formula (I): (Formula (I)) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.  
WO/2020/157128A1
A ligand-SiFA conjugate compound represented by formula (1) wherein: RL is a ligand moiety which is capable of binding to prostate-specific membrane antigen (PSMA); RSiFA is a silicon-fluoride acceptor (SiFA) moiety which can be labeled ...  
WO/2020/157177A1
The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F.  
WO/2020/148154A1
The invention concerns a compound according to following formula, wherein R1 is an F or an I residue.  
WO/2020/131918A1
The invention relates to particular prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-p regnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharm...  
WO/2020/119206A1
Disclosed are a radioactive iodine-labelled Larotrectinib compound, a preparation method therefor and the use thereof. The radioactive iodine-labelled Larotrectinib compound includes a radioactive iodine-labelled Larotrectinib compound o...  
WO/2020/115715A1
The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined as set forth in the ...  
WO/2020/108688A1
The Invention relates to a compound of general formula (I), where Ar is a pyridine ring. Also provided is a precursor compound for preparing a compound of formula (I), which has a nucleofuge in place of a group R1.  
WO/2020/103392A1
Disclosed in the present invention are an 18F-PET/CT tracer comprising 7-deazaadenine base as a parent nucleus and a preparation method therefor. Disclosed in the present invention are a compound represented by formula I or a pharmaceuti...  
WO/2020/102596A1
Deuterated polyunsaturated fatty acid ("PUFA") compounds, compositions, and uses of the compounds for reducing lipid autooxidation and the treatment of various diseases and conditions are provided.  
WO/2020/099398A1
A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their u...  
WO/2020/102737A1
Disclosed herein are compounds and methods for labeling and quantifying analytes using mass spectrometry.  
WO/2020/099770A1
The invention relates to a method for transferring a radioisotope that is attached to a first stationary phase contained in a first chromatography column to a second stationary phase contained in a second chromatography column, in order ...  
WO/2020/089379A1
The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the sy...  
WO/2020/088767A1
The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the sy...  
WO/2020/084267A1
The present invention concerns compounds of the following general structure (I): (I) in which A, B, C, D, L1, L2, L3, L4, n and m are as defined in claim 1. The invention also concerns the use of these compounds for an application for ne...  
WO/2020/065047A1
The present invention provides a novel method for the controlled stereoisomerization (comprising the stereo-conversion of chiral compounds to racemates, non-racemic mixtures and mixtures of epimers). The method of the invention provides ...  
WO/2020/059986A1
The present invention relates to a method for preparing a fluorine-18-labeled fluoromethyl-substituted radiopharmaceutical using selective azide substitution reaction, the method comprising: a first step for obtaining [18F]fluoride from ...  
WO/2020/061458A1
The disclosure pertains to drug delivery conjugates for targeted therapy. The disclosure relates to methods of treating PSMA expressing cancers with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac. The disclos...  
WO/2020/053596A1
The invention relates to a process for producing a compound comprising the anion [CF2 18FSO2]-, which process comprises treating a difluorocarbene source with (i) a source of 18F- and (ii) a source of SO2. The invention relates to a comp...  
WO/2020/035782A1
The present invention relates to compounds according to structure (I) whereby one of R1 to R3 is -OCOCD3 and the other two are either hydroxyl or OAc, their synthesis and their use in for the analysis of the metabolism of glycolysis inhi...  
WO/2020/035518A1
In a method (100 to 208) in which hyperpolarizable tracer molecules (20, 88 to 98) are hydrogenated and then optionally also hyperpolarized for magnetic resonance imaging, it is proposed that, in a first method step (104, 202), a hydroge...  
WO/2020/032038A1
The present invention provides a compound represented by formula (I), which has high specificity and high selectivity for monoamine oxidase B, and which is capable of imaging monoamine oxidase B with a good sensitivity, or a pharmaceutic...  
WO/2020/017557A1
Provided are: a compound suitable for imaging an intracerebral TRPV1 receptor; and a use thereof. A compound or a salt thereof represented by formula (I) is used. [In formula (1), R1 is a hydrogen or a random organic group; R2 is an orga...  
WO/2020/010228A1
Disclosed herein, inter alia, are deconstructive functionalization methods and compounds made using the same.  
WO/2020/007893A1
The present invention refers to reagents and methods for preparing a peptide sequence having a [18F]fluoro-aromatic amino acid side which may be further substituted, in particular a 4-[18F]fluoro-phenylalanine side chain in peptide seque...  
WO/2020/002314A1
The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.  
WO/2020/002634A1
The present invention relates to specific nitrogen containing compounds of formulas (I), (II) and (IV) of the present invention, which are suitable to be used in a method to detect alkyne group containing organic compounds by mass spectr...  
WO/2019/236483A1
The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular pro...  
WO/2019/210422A1
The present disclosure relates to Vitamin E derivatives as multi-scale imaging agents. In particular, the present disclosure relates to isotopically labeled Vitamin E derivatives, and their use as multi-scale imaging agents.  
WO/2019/204335A1
The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a compound of the formula 1. The invention described her...  
WO/2019/200131A1
The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the cera...  
WO/2019/193068A1
The present invention relates to a process for the synthesis of a carbon labeled organic compound containing a carbon labeled carboxyl group. The present invention also concerns the use of carbon labeled organic compounds containing a ca...  
WO/2019/192912A1
There is provided a synthesis of [18F]SFB (N-succinimidyl 4-[18F]fluorobenzoate) using a one-step reaction procedure without generating radioactive waste gases. [18F]SFB is useful as a reagent for labeling of low- and high-molecular weig...  
WO/2019/191642A1
Provided herein are methods and labeling kits for synthesizing 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyl-u racil in a one-pot reaction in compliance with CGMP. Also disclosed are labeling kits that can be assembled in an...  
WO/2019/185932A1
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises...  
WO/2019/185933A1
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method...  
WO/2019/186135A1
The present invention relates to radiolabelled olaparib and in particular [ 18 F]olaparib, a process for producing radiolabelled olaparib, and uses of radiolabelled olaparib in medical imaging.  
WO/2019/183186A1
Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 t...  
WO/2019/181017A1
Provided is a novel boron isotope (10B) tracing drug for use in neutron beam dynamic therapy (NBDT) and boron neutron capture therapy (BNCT). The novel boron isotope (10B) tracking-type drug represented by chemical formula 3 exhibits loc...  
WO/2019/175405A1
6-[18HF]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]...  
WO/2019/169815A1
A radioactive molecular probe and an application thereof in detection of intravital islets, its structure is: formula (I), wherein R 1 are halogen, saturated aliphatic hydrocarbon group, unsaturated aliphatic hydrocarbon group and aromat...  
WO/2019/166962A1
Crystalline Form M1 of deutetrabenazine is provided along with methods of its preparation. Deutetrabenazine may be useful in the treatment of a VMAT2-mediated disease and thus crystalline Form M1 of deutetrabenazine may be incorporated i...  
WO/2019/166537A1
The present invention describes novel chelators (multidentate ligands) and precompounds for complexation of radiometals and non-radioactive counterparts, for use in radiopharmacy. The invention includes a process and a kit involving such...  
WO/2019/165290A1
The invention provides a compound as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and methods for using such compounds and compositions. Formula (I).  
WO/2019/158634A1
The present invention relates to deuterated derivatives of 9-(2,5-difluorophenethyl)-4- ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one having pharmacological activity, to processes of preparation of such compounds, to pharmaceutic...  

Matches 1 - 50 out of 2,127